- You Down With CGT? February 18, 2019
- FDA Announces Various Initiatives to Increase Oversight of the Dietary Supplement Industry February 15, 2019
- FDA Issues Final Guidance on Least Burdensome Provisions February 13, 2019
- FDA’s Tenth Annual Report to Congress on 505(q) Citizen Petitions: New Numbers and the Same Message February 12, 2019
- And the Nominees Are…. FDA Law Blog’s Top 10 Device Posts of 2018 February 11, 2019
- Big Molecule Watch Blog
- Bloomberg BNA Health Care Blog
- Drug and Device Law Blog
- Eye on FDA
- FDA Matters
- Harvard Law Bill of Health
- IN VIVO Blog
- Internet Drug News.com
- Lachman Consultants Blog
- Medical Devices Today
- Orange Book Blog
- Patent Baristas
- Patent Docs
- Pharma IQ
- Pharmalot
- SCOTUS Blog
- The Volokh Conspiracy
- WLF Legal Pulse
- Advertising and Promotion (Federal Trade Commission)
- Advertising and Promotion (OPDP)
- Animal Drugs and Feeds
- Biosimilars
- Cannabis
- cGMP Compliance
- Consumer Product Safety Commission
- Controlled Substances
- Cosmetics
- Current Affairs
- Dietary Supplements
- Drug Development
- Drug Enforcement Administration
- Enforcement
- FDA News
- Foods
- Foods and Dietary Supplements
- Fraud and Abuse
- Government Pricing
- Hatch-Waxman
- Health Care
- Health Privacy
- Import/Export
- In Vitro Diagnostic Devices
- Jobs
- Medical Devices
- Miscellaneous
- Orphan Drugs
- OTC Drugs and Cosmetics
- Prescription Drugs and Biologics
- Product Jurisdiction and Combination Products
- Reimbursement
- Tissue Products
- Tobacco
- Uncategorized
Sen. Leahy Asks DOJ for Update on Investigation of Peanut Corporation of America
February 23, 2011By Ricardo Carvajal –
In a letter directed to Attorney General Eric Holder, Senator Patrick Leahy (D-VT) asked the U.S. Department of Justice (“DOJ”) for an update on its investigation of the Peanut Corporation of America (“PCA”) and its president, Stewart Parnell. According to the letter, FDA determined that PCA knowingly distributed potentially contaminated food, and evidence suggests that PCA shopped for a testing laboratory that would provide favorable results. Sen. Leahy contends that “it is critical [for DOJ] to determine whether these actions rise to the level of criminal conduct.” The letter also cites the recent pistachio recall and egg-related salmonella outbreak as evidence that “wrongdoers are disregarding the health and safety of American consumers by choosing to sell contaminated products.” The letter closes by noting that Sen. Leahy has introduced legislation to impose tougher penalties for certain food safety violations, and asks whether DOJ “needs any additional tools to protect the American people.”
Search FDA Law Blog
Subscribe
Enter your email address to automatically receive new posts to the FDA Law Blog via e-mail.
Latest Tweets
Tweets by @fdalawblogAwards & Honors
- The Best
Lawyers in America
US News & World Report - Ranked in Chambers USA 2018
- You Down With CGT? February 18, 2019
- FDA Announces Various Initiatives to Increase Oversight of the Dietary Supplement Industry February 15, 2019
- FDA Issues Final Guidance on Least Burdensome Provisions February 13, 2019
- FDA’s Tenth Annual Report to Congress on 505(q) Citizen Petitions: New Numbers and the Same Message February 12, 2019
- And the Nominees Are…. FDA Law Blog’s Top 10 Device Posts of 2018 February 11, 2019
- Big Molecule Watch Blog
- Bloomberg BNA Health Care Blog
- Drug and Device Law Blog
- Eye on FDA
- FDA Matters
- Harvard Law Bill of Health
- IN VIVO Blog
- Internet Drug News.com
- Lachman Consultants Blog
- Medical Devices Today
- Orange Book Blog
- Patent Baristas
- Patent Docs
- Pharma IQ
- Pharmalot
- SCOTUS Blog
- The Volokh Conspiracy
- WLF Legal Pulse
- Advertising and Promotion (Federal Trade Commission)
- Advertising and Promotion (OPDP)
- Animal Drugs and Feeds
- Biosimilars
- Cannabis
- cGMP Compliance
- Consumer Product Safety Commission
- Controlled Substances
- Cosmetics
- Current Affairs
- Dietary Supplements
- Drug Development
- Drug Enforcement Administration
- Enforcement
- FDA News
- Foods
- Foods and Dietary Supplements
- Fraud and Abuse
- Government Pricing
- Hatch-Waxman
- Health Care
- Health Privacy
- Import/Export
- In Vitro Diagnostic Devices
- Jobs
- Medical Devices
- Miscellaneous
- Orphan Drugs
- OTC Drugs and Cosmetics
- Prescription Drugs and Biologics
- Product Jurisdiction and Combination Products
- Reimbursement
- Tissue Products
- Tobacco
- Uncategorized